From "Xinda Ding" to "Wukong": Innovent Biologics and DingTalk Deepen AI Strategic Partnership

On April 27, Innovent Biologics, Ltd. and DingTalk officially signed a framework cooperation agreement. The two parties will deepen their collaboration, expanding from office coordination to the application of artificial intelligence, with a key focus on implementing the "Wukong" pilot program to help revolutionize work practices across the entire group in the AI era. Dr. De-Chao Yu, Founder, Chairman of the Board, and CEO of Innovent Biologics, attended the signing ceremony together with Chen Hang, founder of DingTalk and Wukong, and completed the signing.

Innovation-Driven Development, Global Strategic Planning

Innovent Biologics is a leading innovative biopharmaceutical company in China and a national high-tech enterprise, focusing on research, development, manufacturing, and commercialization of innovative medicines for major diseases including oncology, autoimmune disorders, metabolic diseases, and ophthalmology. Its core product in the metabolic field, Mazdutide, is the world's first and only approved natural dual-targeting GCG/GLP-1 therapy for weight loss and glucose control, demonstrating outstanding fat-burning and liver-protective effects, with the potential to benefit hundreds of millions of patients with metabolic diseases. Currently, the company is leveraging an intelligent end-to-end production system and a globally synchronized R&D network to accelerate its strategic vision of "innovation as the foundation, moving toward globalization."

Deepening AI Collaboration, Empowering Smart Medicine

The biopharmaceutical industry demands exceptionally high standards in efficiency, compliance, and innovation capability. Although AI applications face significant barriers, continuous investment remains essential. Previously, Innovent and DingTalk jointly developed “Innovent-Ding,” a customized mobile working platform that has laid a solid foundation for digital transformation. Facing intensified industry competition and rapid penetration of AI technologies, Innovent has further clarified its AI strategy. This upgraded partnership will deeply integrate the AI capabilities of DingTalk and Wukong to provide intelligent support for all employees.

Dr. Yu said: "We have enjoyed many years of close collaboration with DingTalk, and 'Innovent-Ding' has become the core platform for team coordination. The enhanced AI capabilities, especially those offered by Wukong, will provide powerful tools to support Innovent’s comprehensive adoption of AI. We also hope to co-develop industry-specific features through this partnership, creating value for the broader biopharmaceutical sector."

Building an AI Ecosystem, Exploring Intelligent Agent Applications

Basing on strategic alignment, both sides will strengthen cooperation in optimizing AI collaboration platforms and co-building AI-driven business scenarios, accelerating the implementation of Innovent’s AI strategy.

Regarding AI workplace infrastructure, the upgraded "Innovent-Ding" platform will incorporate flagship AI features such as AI meeting notes and AI spreadsheets. In talent development and joint innovation, tiered AI training programs will be rolled out across the organization. Through AI bootcamps and innovation competitions, internal AI pioneers will be cultivated. Additionally, a joint AI Innovation Lab will be established to focus on incubating high-value AI solutions tailored for the biopharmaceutical industry.

On this foundation, both parties will actively advance the Wukong pilot program and expand its integration into real business operations. With Wukong, Innovent will launch enterprise-level AI agent pilots, exploring two key pathways—security and compliance verification, and human-AI collaboration models—to assess the feasibility of using AI agents to replace high-frequency repetitive tasks.

This strategic collaboration represents not just a technological leap in tools, but also a deep exploration of practical AI applications, helping Innovent build robust, in-depth AI capabilities. Chen Hang said: "Innovent Biologics is a truly globally competitive player in China's innovative drug sector. We hope this partnership will allow us to shape a new paradigm for pharmaceutical companies in the AI era and set a new benchmark for digital and intelligent transformation in the biopharmaceutical industry."

We dedicated to serving clients with professional DingTalk solutions. If you'd like to learn more about DingTalk platform applications, feel free to contact our online customer service or email at This email address is being protected from spambots. You need JavaScript enabled to view it.. With a skilled development and operations team and extensive market experience, we’re ready to deliver expert DingTalk services and solutions tailored to your needs!